Clinical Trial Update: XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating XELOX plus Dostarlimab vs XELOX alone as consolidation after chemoradiation in pMMR/MSS or MSI-Low locally advanced rectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)
• Dostarlimab (Jemperli) (dostarlimab)
• Oxaliplatin (Eloxatin) (oxaliplatin)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Locally Advanced Rectal Cancer (LARC) | Phase 2 | Status: NOT_YET_RECRUITING